TD Asset Management’s Palisade Bio PALI Stock Holding History

TD Asset Management’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-204,448	Closed	-$480K	–	1279
2025 Q4	$480K	Buy	+204,448	New	+$393K	﹤0.01%	1173

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

TD Asset Management's PALI Position: Q1 2026 in Review

TD Asset Management sold out of Palisade Bio (PALI) in Q1 2026, closing a stake of 204,448 shares — an estimated $480K sold.

TD Asset Management first reported a position in PALI in Q4 2025 and held it in 1 quarter. The position peaked at $480K in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

TD Asset Management reported no remaining Palisade Bio position as of Q1 2026 after selling out during the quarter.
TD Asset Management sold 204,448 Palisade Bio shares in Q1 2026, an estimated $480K.
TD Asset Management first reported a position in Palisade Bio in Q4 2025 and held it in 1 quarter.
TD Asset Management's Palisade Bio position peaked at $480K in Q4 2025.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.